Methods: This was a single-arm, non-randomized pilot study of carboplatin, taxane, and immune checkpoint inhibitor, pembrolizumab, followed by 12 months of maintenance pembrolizumab in patients with incompletely resected epithelial ovarian cancer (EOC). Results: A total of 29 patients...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1923, 127 (2022). https://doi.org/10.1007/s40278-022-22990-2 Download citation Published10 September 2022 Issue DateSeptember 2022 DOIhttps://doi.org/10.1007/s40278-022-22990-2 Access this article Log in via an institution Buy article PDF...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1955, 121 (2023). https://doi.org/10.1007/s40278-023-38368-3 Download citation Published06 May 2023 Issue DateMay 2023 DOIhttps://doi.org/10.1007/s40278-023-38368-3 Access this article Log in via an institution Subscribe and save Springer...
The study KEYNOTE-407 investigated pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel or chemotherapy alone in patients with stage IV squamous NSCLC who had not received previous systemic therapy for metastatic disease.4 The addition of pembrolizumab to the chemotherapy ...
Four patients of the 23 evaluable patients (per protocol population) had a partial response (PR), leading to an ORR of 17% (95% confidence interval (95% CI) of 5–39%), with two responses being short-lived. The median duration of response was 14.9 weeks. Two additional patients had st...
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol, 20 (2019), pp. 924-937 View...
Selected KEYTRUDA® (pembrolizumab) Indications in the U.S. Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary...
Background: The treatment-free interval is a significant predictor of worse prognosis and poor response rates of the second-line treatment in patients with carboplatin and paclitaxel (PT)-pretreated, advanced, or recurrent endometrial cancer (EC). Whether lenvatinib plus pembrolizumab still confers a ...
There were no new safety signals.#Pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity and a manageable safety profile in first-line R/M HNSCC, suggesting this combination may be an alternative option for this patient population.Marcin Dzienis...
Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer 8 (Suppl. 3): A118 abstr. 201, 2020. Available from: URL: http://doi.org/10.1136/jitc-2020-SITC2020.0201 [abstract]...